№ files_lp_4_process_3_086555
File format: docx Character count: 1948 File size: 56 KB
This document outlines a new method for cancer therapy through Oncostatin M (OSM) Antagonists, showing potential in preventing tumor cell detachment, invasion, and metastasis across various cancer types.
Year: 2023
Region / city: United States
Field: Health and Medical Sciences, Cancer Therapy
Document Type: Research Publication
Organization: Boise State University
Author: Cheryl Jorcyk, PhD; Don Warner, PhD; Lisa Warner, PhD; Matthew D. King
Target Audience: Researchers, Healthcare Professionals, Oncology Specialists
Development Stage: Preclinical / Research
Date of Approval: N/A
Date of Changes: N/A
IP Status: Patents Issued
Patents: 9,550,828, 10,286,070, 11,633,457
Phase of Development: TRL 3-4, Working Prototype
Contact Information: Office of Technology Transfer, [email protected]
Note: , (208) 426-5765
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Risk Assessment (OSM): Pitching and Striking Tents – 10 September 2024
Date of risk assessment: 10th September 2024
Date of next review: 9th September 2026
Name of person conducting assessment: Iain Roy
Category (OSM): Activities
Activity: Pitching and Striking Tents
Identified hazards: Unqualified leaders, lack of safety awareness, overexcitement, slips trips and falls, manual handling injuries, tent pole injuries, unforeseen hazards
Persons at risk: Young people, Leaders
Existing controls: Designated Leader In Charge, shared planning materials, clear roles and responsibilities, safety briefings, section code of conduct, supervision, equipment checks, weather assessment, safe lifting guidance, first aid provision, dynamic risk assessment in line with TSA guidelines
Additional controls: Closer supervision for children with SEN, relocation of activity area if required
Risk Assessment (OSM) Urban Hike – 10th September 2024
Year: 2024
Date of risk assessment: 10th September 2024
Date of next review: 9th September 2026
Category (OSM): Hikes
Activity type: Urban Hike
Assessor: Iain Roy
Participants: Young people (Squirrels, Beavers, Cubs, Scouts) and Leaders
Leader ratios: 1:4 (Squirrels) +1 minimum; 1:6 (Beavers) +1 minimum; 1:8 (Cubs) +1 minimum; 1:12 (Scouts) +1 minimum
Safeguarding framework: Yellow Card rules
Training requirements: Up to date First Response Training; qualified first aider in attendance
Communication measures: Mobile phones carried by adults; emergency services contact procedures; whistle stop signal
Weather considerations: Wet, cold, and extreme weather precautions including postponement if required
Primary hazards identified: Behavioural risks, safeguarding issues, first aid incidents, traffic and railway crossings, slips/trips/falls, lost or abducted participant, unsafe objects, stings, extreme weather, unforeseen hazards
Control measures: Route planning and route cards, headcounts and register, supervision ratios, high visibility clothing, safety briefings, dynamic risk assessment in line with TSA guidelines
WOF 044 OSM ‘EXCEPTIONAL CIRCUMSTANCES’ REPORTTO Natural Resources Wales
Year: 2025
Region / City: North Gwent
Subject: Wastewater Treatment Incident Report
Document Type: Incident Report
Organization: Dwr Cymru Welsh Water
Author: Mark Greenslade
Target Audience: Environmental and Regulatory Authorities
Period of Action: 21/11/2025 - 26/11/2025
Date of Approval: Not provided
Date of Changes: Not provided
Topics: Oncostatin Antagonist OSM